Associate Director External Innovation DPDS
Why I'm a JPAL
Identifying the most promising angle of an emerging technology, and then move it forward towards applicability is a challenging task. I consider it a privilege to interact with young companies to address those challenges together.
I’ve joined JnJ in 2014 through the acquisition of Covagen, an ETH Zuerich spin-off company developing bispecific protein therapeutics. Within JnJ, I worked in early RnD covering the fields of both immuno-oncology and auto-immune disease. Prior to JnJ, I’ve done post-doctoral research studies in the field of Stem Cell and Regenerative Biology, studying genetic and epigenetic mechanism of cellular identity. In 2019, I had the opportunity to join Janssen’s DPDS (Discovery, Product Development and Supply) External Innovation Team. My previous scientific experiences helped me to quickly grasp the essentials of this exciting role. I love being part of Janssen’s mission to translate the findings in biomedical research – independent of their origin - into solutions for the benefit of patients.
"He who has a why to live can bear almost any how."
After my PhD, I travelled South America by bike for half a year.